中等度から重度の活動性潰瘍性大腸炎患者を対象としたチルピセルチブ・ホスメカルビルの研究

基本情報

NCT ID

NCT06029972

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

176

治験依頼者名

Gilead Sciences

概要

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.

対象疾患

介入

依頼者（Sponsor）

実施施設 (12)